prostate adenocarcinoma transcutaneous hormones patch study large randomized controlled trial united kingdom highdose transdermal estradiol patches versus gonadotropinreleasing hormone agonist therapy treatment prostate cancer specifically comparing three four Î¼gday estradiol patches femseven progynova ts goserelin implants approximately men prostate study started march estimated completion august additional reports expected objectives include comparison survival cardiovascular mortality morbidity pharmacological activity eg suppression testosterone levels side effects toxicities quality report longterm cardiovascular outcomes published february reports study also besides patch trial systemic therapy advancing metastatic prostate cancer evaluation drug efficacy stampede trial also united kingdom added highdose transdermal estradiol patches arm approximately men july